Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (151-160 of 198) with videos related to

Pageof 20
Sort By:
Annals of the Rheumatic Diseases|July 15, 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, et al.
Rheumatology (Oxford, England)|December 15, 2010
Registries in systemic sclerosis: a worldwide experienceFelice Galluccio, Ulrich A Walker, Svetlana Nihtyanova, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
The Journal of Rheumatology|March 4, 2014
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trialMark C Genovese, César Pacheco Tena, Arturo Covarrubias, et al.
Pageof 20

Showing results (151-160 of 198) with videos related to

Sort By:
Pageof 20
Annals of the Rheumatic Diseases|July 15, 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, et al.
Rheumatology (Oxford, England)|December 15, 2010
Registries in systemic sclerosis: a worldwide experienceFelice Galluccio, Ulrich A Walker, Svetlana Nihtyanova, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
The Journal of Rheumatology|March 4, 2014
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trialMark C Genovese, César Pacheco Tena, Arturo Covarrubias, et al.
Pageof 20